Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

BETHESDA, Md., March 13 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the fourth quarter and the full year ended December 31, 2007. As a result of the reverse merger between Micromet AG and CancerVax Corporation that was completed on May 5, 2006, the financial information included below for the fiscal year 2006 consists of Micromet AG's historical financial results for the period of January 1, 2006 to May 5, 2006 without the inclusion of the financial results of CancerVax, and the combined results of the two companies thereafter.

Summary of Recent Events:

-- Micromet published data on its BiTE(R) antibody MT103 at the annual

meeting of the American Society of Hematology in December, showing that

MT103 induces dose-dependent objective complete and partial responses

in late stage lymphoma patients. The BiTE antibody could also clear the

bone marrow and other infiltrated organs from tumor cells. Particularly

encouraging was the observation of complete responses in patients with

mantle cell lymphoma (MCL) -- a disease that is difficult to treat. In

Europe, Micromet has initiated a phase 2 study in acute lymphoblastic

leukemia, one of the most aggressive blood cancers.

-- Micromet has completed preclinical development for its second BiTE

antibody MT110. MT110 binds to EpCAM, a cell surface molecule that is

highly expressed on many solid tumors and on cancer stem cells -- those

cancer cells responsible for metasta
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... Biotechnology Company, Limited ("TaiGen") today announced that they have ... pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ® ... Turkey and other members of ... for the treatment of bacterial infections including those caused ...
(Date:1/14/2014)... 14, 2014 As pet owners drew up their lists of ... wrote: "Take better care of my furry companion." Nowadays there are ... top-brand carrying cases to take the little canine or feline darlings ... compelled to buy some pricey toys at the pet store. But ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 In recent ... motives and methods in product development and promotion has ... industry. This mistrust, fueled by concerns about the insidious ... by reports of spectacular fines to the world’s biggest ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
(Date:4/23/2014)... diner ripping open a dinner roll, a fuel cell ... a hydrogen molecule. Now researchers have captured a view ... of its hydrogen feast. The view confirms previous hypotheses ... work better for alternative energy uses. , This study ... the hydrogen halves end up in the structure of ...
(Date:4/23/2014)... the source of a unique rhythmic sound, recorded for ... is the Antarctic minke whale ( Balaenoptera bonaerensis ). ... 1960s who thought it sounded like a duck, the ... the Southern Ocean, but its source has remained a ... team of researchers deployed acoustic tags on two Antarctic ...
(Date:4/23/2014)... Buenos Aires yesterday, Argentina joins the European Molecular ... The move strengthens the ties between the European ... Argentinian scientists access to EMBL,s world-class facilities and ... since its inception, fostering excellent life science research ... core of EMBL,s mission," says EMBL Director General ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3
... Species of mammals and birds are threatened with extinction as ... McKee and colleagues from The Ohio State University in the ... the exponential growth of the human population will continue to ... does not appear to be a threshold above which population ...
... at the University of Pittsburgh has developed antibacterial compounds, ... be potential treatments for drug-resistant bacterial infections and appear ... small, making them inexpensive and easy to manufacture. The ... the journal Antimicrobial Agents and Chemotherapy . ...
... MINNETONKA, Minn. , June 19, 2013 MedNet ... clinical study management systems, is pleased to announce its participation ... 23-27 in Boston .  This represents the ... cloud-based eClinical solutions, has exhibited at this premier industry event. ...
Cached Biology News:Are we pushing animals over the edge? 2HIV-derived antibacterial shows promise against drug-resistant bacteria 2MedNet Solutions To Spotlight iMedNet EDC At The 49th DIA Annual Meeting 2
SphingoStripsTM contain fifteen different biologically active, nitrocellulose-immobilized lipids at 100 pmol per spot, which can be assayed for protein binding and specificity using a simple blot ove...
Mouse monoclonal antibody raised against a partial recombinant KRT4. NCBI Entrez Gene ID = KRT4...
... PrecisION Ion Channel Cell Lines ,High ... ,Ion channels are well known for having ... function and consequently have a key function ... that modulate ion channels have been investigated ...
... Channel Cell Lines ,High Quality, Functionally-Validated, Ion ... well known for having a critical role ... have a key function in pain, CNS ... channels have been investigated in therapeutic areas, ...
Biology Products: